Phase III study of bilayer sustained-release tramadol tablets in patients with cancer pain: a double-blind parallel-group, non-inferiority study with immediate-release tramadol capsules as an active comparator

ConclusionTwice-daily administration of bilayer tramadol tablets was as effective as four-times-daily administration of IR capsules regarding the improvement in pain VAS, with comparable safety outcomes.Clinical trial registrationJapicCTI-184143/jRCT2080224082 (October 5, 2018).
Source: Supportive Care in Cancer - Category: Cancer & Oncology Source Type: research